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Squaramides with cytotoxic activity against human
gastric carcinoma cells HGC-27: synthesis and
mechanism of action†‡
Mireia Quintana,§a Juan V. Alegre-Requena,§ab Eugenia Marqués-López,b
Raquel P. Herrera*b and Gemma Triola*a
A series of squaramates and squaramides have been synthesized and their cytotoxic activity has been in-
vestigated in different cancer cell lines. Among the studied compounds, squaramide 34 showed a potent
and selective cytotoxicity against the human gastric cancer cell line HGC-27. Studies directed to elucidate
the mechanism of induced cell death were performed. Cell cycle distribution analysis and cell death studies
showed that compound 34 induces cell cycle arrest at the G1 phase and caspase-dependent apoptosis. In
conclusion, squaramide 34 can be considered a potential anticancer agent for gastric carcinoma.
1. Introduction
The field of squaramides has experienced an extraordinary
growth since the work reported by Rawal and co-workers in
2008,1 where these molecules were used as organocatalysts.
Their promising properties also make them appealing for di-
verse areas of research beyond organocatalysis.2–4
Their unique structural features are believed to have an
effect on the biological activity of these substrates;
squaramide structures present a planar aromatic framework5
bearing two adjacent carbonyl acceptor groups and two NH
donor sites that are able to establish multiple hydrogen
bond interactions.6 In this sense, due to their important abil-
ity to selectively bind through cooperative hydrogen bonds,
squaramides have received special attention in medicinal
chemistry since they may be able to interact with biological
targets via specific molecular recognition.7
This has promoted recent interest of medicinal chemists
in considering squaramide motifs as promising candidates
for drug design and interesting tools as bioisosteres of ureas,
guanidines or phosphates, among others.8–16 Moreover,
squaramides exhibit an interesting dual behaviour, as they
are able to act as good hydrogen bond acceptors and hydro-
gen bond donors, which make them suitable for both cation
and anion recognition. This could be crucial for the success
of cell internalization of these compounds, one of the most
important issues in drug design.
In spite of the increasing number of bioactive squaramide-
based compounds found in the literature, their application as
anticancer agents has not yet been intensively explored and
no exhaustive studies in different cancer cells have been pre-
viously reported.17,18 In addition, some squaramides have
been shown to selectively bind protein kinases18 or the
CXCR2 receptor,19 thus indicating that this class of com-
pounds may exert their function by selectively binding to cel-
lular targets. Hence, this interesting behaviour suggests that
squaramides may serve as a good starting point to identify
molecules that can specifically target cancer cells. This, to-
gether with the interest in searching for new anticancer
agents, prompted us to evaluate the antitumor activity of a
variety of squaramides synthesized following a protocol re-
cently published by us.20–22
Based on these precedents, we envisioned that the ability
of squaramides to generate hydrogen bonds and electrostatic
interactions could be an interesting option to design specific
recognition systems with potential antitumor effects. Herein,
we present a series of squaramides and squaramates and the
study of their activity against different cancer cells that con-
firms the antitumor properties of this family of promising
drug candidates.
2. Results and discussion
Firstly, following our optimized reaction conditions,20,22 a
series of differently substituted squaramates 1–14 and
squaramides 15–39 were synthesized (Charts 1 and 2). Sub-
stituents with different stereoelectronic properties and
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lipophilicities were incorporated with the aim of investigat-
ing if their biological activity may correlate with the pres-
ence of different NH amide-type donor sites.
2.1. Cell-type specific cytotoxic effect of squaramides
The effect of squaramides on cell viability was initially evalu-
ated on different tumor cell lines (HeLa, cervical carcinoma,
and HGC-27, gastric carcinoma) using an MTT assay after
24 h of treatment at 100 μM (Fig. 1).
As shown in Fig. 1, treatment with some of the com-
pounds resulted in significant loss of cell viability. Some
structure–activity relationships can be disclosed from this
initial screening. Hence, squaramates 1–14 (Chart 1) showed
no remarkable activity in any of the cases, thus indicating
that the second NH amide bond is required for activity.
Chart 1 Squaramates and squaramides evaluated.
Chart 2 Squaramides evaluated.
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Substantial inhibition can be seen for compounds 15–20 all
of them sharing a cinchona-based substituent. Interestingly,
the presence of a 3,5-bisĲtrifluoromethyl)phenyl moiety con-
fers almost in all the cases inhibition of cell viability (15, 16,
21, 27, 34–38), irrespective of the other substituent present at
the second amide. Similarly, 3,5-bisĲtrifluoromethyl)benzyl
substituted squaramides 22 and 26 also show good activities
in HGC-27 cells, whereas they are less active in HeLa cells.
After this initial screening, the most potent compounds
were selected and were further evaluated at 20 μM (Fig. 2).
Interesting information was revealed from this second
screening. In general, HGC-27 cells seem to be more sensitive
than HeLa cells to the effect of the tested squaramides, ex-
cept for compound 27 which shows a more potent cell viabil-
ity inhibitory activity in HeLa cells than in HGC-27. This cell-
type specificity may discard a general non-specific cytotoxic
effect exerted by the squaramides. Again, the cinchona-based
compounds 15–20 showed good inhibitory activities, inde-
pendently of the substituents present at the other point of
diversity. Squaramides containing bulky and chiral substitu-
ents at both sites (25, 39) are more potent than the cor-
responding p-trifluoromethylphenyl analogues (29, 30). The
3,5-bisĲtrifluoromethyl)phenyl substituted squaramides 34–38
displayed different potencies depending on their substitution
pattern, with the highly lipophilic 33 and 34 being the most
potent compounds. As a result of this second screening,
squaramides 21, 22, 28–30, 32 and 35–37 were discarded due
to the low potency displayed at 20 μM and, consequently, IC50
values were measured for the remaining compounds (Table 1).
The increased sensitivity of HGC-27 cells compared to
HeLa cells was again proven, showing in all the cases IC50
values in the low micromolar range for all the tested
squaramides. Interestingly, squaramide 34, bearing a 1,1,2-
triphenylethanol and a 3,5-trifluoromethylphenyl substituent,
Fig. 1 Percentage of cell viability after 24 h of treatment with a concentration of 100 μM as measured by an MTT assay. The cells were grown on
a 96-well plate and treated with the squaramides or DMSO (vehicle group). After 24 h of treatment, cell viability was evaluated using an MTT assay,
as described in the Experimental section. Cell viability is represented in relation to the vehicle group. Data are the average ± SD of three
experiments.
Fig. 2 Percentage of cell viability after 24 h of treatment with a concentration of 20 μM as measured by an MTT assay. The cells were grown on a
96-well plate and treated with the squaramides or DMSO (vehicle group). After 24 h of treatment, cell viability was evaluated using an MTT assay,
as described in the Experimental section. Cell viability is represented in relation to DMSO. Data are the average ± SD of three experiments. Note:
compounds 29, 30 and 33–35 were not investigated in HeLa cells at 20 μM.
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was found to be one of most potent and selective compounds
tested, showing an IC50 value of 34.63 μM in HeLa cells
and 1.81 μM in HGC-27 cells. Analogously, squaramide 33,
where the 3,5-bisĲtrifluoromethyl)phenyl had been replaced by
3,5-difluorophenyl, displayed a similar activity pattern. More-
over, this low micromolar IC50 decreased further to nano-
molar values (660 nM, Table 2) when HGC-27 cells were
exposed to compound 34 for 48 h.
With these promising results in hand regarding the activ-
ity and selectivity of squaramide 34, we decided next to ex-
plore the activity profile of 34 on different cell lines. Hence,
cell viability studies were extended to the glioblastoma cells
lines, T98 and U87 (the most aggressive type of primary brain
tumor) and the non-cancer cells HEK293, MDCK (Madin-
Darby Canine Kidney Epithelial cells) and the Vero cell line
(African green monkey kidney cell line). The results are
displayed in Table 2 and confirm certain cell-dependent tox-
icity (IC50 values of 60.25 μM and 7.15 μM for the glioblas-
toma cell lines U87 and T98, respectively, 9.03 μM for the
HEK293 cells, 70.20 μM for the MDCK cells and 33.40 μM for
the Vero cells).
Gastric cancer accounts for 8% of the total cases of can-
cers and 10% of total deaths. The survival for patients with
this type of cancer has improved only modestly over the last
50 years. Consequently, there is still a clear need for the de-
velopment of more efficient treatments. Moreover, gastric
cancer presents high molecular heterogeneity, which prevents
the uniform application of specific targeted agents,23 and
therefore the identification of novel targets or novel com-
pounds active on gastric cancer cells is of great interest.23,24
With this aim, and due to the high potency displayed by 34
in the gastric cancer cells HGC-27 together with its interest-
ing selectivity profile observed in the other cell lines, we
aimed to further examine the molecular mechanisms under-
lying 34-mediated cell death in HGC-27 cells.
2.2. Apoptotic cell death study
The MTT assay reflects viable cells but cannot be employed
as a marker of cell proliferation. A decrease in the number of
viable cells can be attributed to cell cycle arrest and/or cell
death. To determine whether 34-induced decrease in cell via-
bility in HGC-27 cells was accompanied by alterations in cell
cycle distribution, the percentage of cells in the different
stages of the cell cycle was analysed by flow cytometry. As
shown in Fig. 3, treatment with 34 for 24 h induced a signifi-
cant accumulation of G0/G1 cells associated with a decrease
in the S–G2/M cell population, suggesting that cell cycle
arrest at the G0/G1 phase contributes to the observed effect,
whereas treatment of cells with doxorubicin, included as a
positive control, resulted in G2/M arrest.
Cell death can be controlled by several mechanisms or
pathways.25 Therefore, we decided to quantify the cell death
caused by 34 as well as determine the specific cell death
modality, which is mainly apoptosis, necrosis or autophagy
that may be prevalent in these cells. With this aim, we evalu-
ated the apoptotic effect of 34 on HGC-27 cells using an
Annexin V-FITC/PI staining assay and analysed the stained
cells by flow cytometry.26 Briefly, loss of plasma membrane
integrity is indicative of cell death and this can be assessed
using cell-impermeable dyes that are able to enter the cell
once the integrity of the plasma membrane is lost, such as
propidium iodide (PI). Moreover, apoptotic cells expose
phosphatidylserine (PS) before membrane rupture, whereas
in necrotic cells PS exposure and membrane disruption occur
simultaneously, thus discriminating early and late apoptotic
cells as well as necrotic cells. To study the effect of 34 on
HGC-27 cells, cells were treated with the vehicle alone as con-
trol or with 34 at three different concentrations (1, 2.5 and
8 μM). After 24 hours, the samples were double stained with
Annexin V-FITC and PI and the percentage of cells was
analysed. As shown in Fig. 4, compound 34 induced cell apo-
ptosis in a concentration-dependent manner. In the case of
1 μM, 2.5 μM and 8 μM treated HGC-27 cells, the total per-
centage of early and late apoptotic cells were 2.4%, 24.7%,
Table 1 Effect of squaramides on cell viability against HeLa and HGC-27
cell lines as measured by an MTT assay. Cisplatin and doxorubicin were
added as a positive control. IC50 values are indicated as the average ± SD
of three experiments
Compound
Mean IC50 (95% CI) in μM
HeLa cells HGC-27 cells
15 11.26 (10.33–12.2) 8.12 (7.14–9.24)
16 15.17 (13.2–17.4) 8.21 (7.68–8.78)
17 10.79 (9.49–12.26) 4.53 (3.83–5.36)
18 >20 12.76 (11.84–13.7)
20 12.08 (11.37–3.93) 3.01 (2.26–5.02)
25 >20 11.11 (10.51–11.74)
33 >20 3.39 (2.85–4.04)
34 34.63 (27.97–42.87) 1.81 (1.47–2.23)
39 >20 10.79 (10.30–11.20)
Cisplatin — 20.44 (19.84–22.18)
Doxorubicin — 37.40 (30.63–45.67)
Table 2 Effect of squaramide 34 on cell viability against various human cancer cell lines as measured by an MTT assay. IC50 values are indicated as the
mean ± SD of three experiments
Compound
Mean IC50 (95% CI) in μM
HeLa HGC-27 T98 U87 HEK293 MDCK Vero
34 34.63
(27.97–42.87)
1.81 (1.47–2.23) 7.15
(6.12–8.34)
60.25
(41.52–87.42)
9.03
(7.07–11.54)
70.20
(50.58–97.43)
33.40
(27.96–39.90)0.66a
(0.57–0.76)
a IC50 measured after 48 h of treatment.
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Fig. 3 Cell cycle distribution of HGC-27 cells with or without treatment of compound 34 at 5 μM in DMSO for 24 h. Doxorubicin (500 nM) was
included as a positive control. The cells were collected and processed for cell cycle analysis. A) Representative cell cycle histograms obtained from
HGC-27 cells after 24 h of exposure to vehicle or 34. B) Quantification of the relative number of cells in each stage of the cell cycle (Multicycle
AV software). Data are the average ± SD of three experiments.
Fig. 4 Apoptotic effect of squaramide 34 on HGC-27 cells. Cells were treated with DMSO (vehicle group) or 34 alone or together with Z-VAD-
FMK (20 μM), Z-IETD-FMK (20 μM), Z-LEHD-FMK (20 μM), Nec-1 (10 μM) or cathepsin inhibitor III (10 μM). Cells were pre-treated for 1 h with
Z-VAD-FMK, Z-IETD-FMK, Z-LEHD-FMK and cathepsin inhibitor III and 3 h with Nec-1 before adding 34. C8-ceramide (20 μM) was added as a
positive control. After 24 h of treatment, the cells were double-stained with Annexin V and PI and analysed. The percentage of apoptotic and ne-
crotic cells upon incubation with 34 were quantified by flow cytometry as described in the Experimental section (live cells (bottom left quadrant),
early apoptotic cells (bottom right quadrant), late apoptotic cells (upper right quadrant) and necrotic cells (upper left quadrant)). The graph shows
the quantitative analysis of necrosis and early and late apoptosis in treated cells. The data were obtained from three independent experiments.
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and 60.1%, respectively. In contrast, only 6.7% of the early
and late apoptotic cells were detected in the control, which
revealed that compound 34 efficiently induces apoptosis in
HGC-27 cells (Fig. 4). Doxorubicin and cisplatin have been
used for the treatment of gastric cancer, usually in combina-
tion with other anticancer agents. Therefore, the effect of
doxorubicin in HGC-27 cells was also investigated, resulting
in dose-dependent induction of apoptosis. HGC-27 cells
treated with a concentration of 2 μM of doxorubicin27
presented 3.2% of early apoptotic cells, 16.7% of late apopto-
tic cells and 32.4% of necrotic cells, thus showing a slightly
less potent effect than squaramide 34.
To explain the high doses required to detect cell death
compared to the IC50 values obtained in the MTT assays, we
measured the effect of these compounds on cell viability by
an alternative assay based on the quantification of cellular
ATP levels. Indeed, although IC50 values resulting from these
studies were in a similar range, the dose-dependent curve
obtained in the ATP-based analysis was in agreement with
concentrations required in cells to cause an apoptotic effect
(Fig. S1‡). Alternatively, a sulforhodamine B (SRB) assay was
employed to investigate the cytotoxicity of 34. SRB is a dye
that binds proteins under mild acidic conditions, and the
amount of detected dye can be correlated with the cell
mass.28 Hence, the SRB assay is independent of the mito-
chondrial function. In this case, an IC50 of 9.74 μM was
obtained for squaramide 34 in HGC-27 cells (vs. 149 μM and
73.85 μM in MDCK and Vero cells, respectively). In contrast
to the MTT assay that requires cellular metabolic activity and
therefore only stains viable cells, SRB stains viable and dead
cells, thus giving generally slightly higher IC50 values.
28
2.3. Squaramide 34 induces caspase-dependent cell death
Apoptosis can be triggered through caspase-dependent or
independent mechanisms. To explore whether 34 induces cell
death through a caspase-dependent mechanism, Z-VAD-FMK,
a pan-caspase inhibitor was employed. Hence, pre-treatment
of cells with Z-VAD-FMK (20 μM) for 1 h partially prevented
34-induced cell death, thus suggesting that a caspase-
dependent mechanism may be involved (Fig. 4).
Apoptosis may be initiated by the extrinsic or the intrinsic
signaling pathway. The extrinsic signaling pathway involves
death receptors located at the membrane, such as FasL/FasR
and TNF-α/TNFR1, the transmission of the signal from the
cell surface to intracellular signaling pathways and the im-
plication of caspase-8. The intrinsic pathway is the mito-
chondrial pathway and may be caused by different stimuli
including free radicals, toxins, or hypoxia, and involves the
activation of caspase-9. The extrinsic pathway and the intrin-
sic pathway converge on the final execution phase, mediated
by the effector caspase-3.29 Hence, we next investigated the
implication of both pathways by pre-treatment of the cells
with a caspase-8 (Z-IETD-FMK) or a caspase-9 (Z-LEHD-FMK)
inhibitor. Interestingly, the percentage of apoptotic cells de-
creased markedly upon treatment with the caspase-9 inhibi-
tor Z-LEHD-FMK, compared to the results obtained with the
other caspase inhibitors, thus suggesting the implication of
the mitochondrial pathway (Fig. 4). A smaller decrease in ap-
optosis rate was also observed when cells were treated with
the caspase inhibitor Z-IETD-FMK, which could be due to the
described cross reactivity for these inhibitors.30
2.4. Alternative cell death mechanism
Cathepsin-dependent cell death. Cell death can also be
mediated by lysosomal cathepsin proteases in the so-called
lysosomal cell death (LCD), consisting of lysosomal mem-
brane permeabilization (LMP) and subsequent release of lyso-
somal proteases to the cytosol.31 Extensive LMP leads to
uncontrolled necrosis, whereas limited LMP can activate
caspase-dependent or independent pathways,32 resulting in a
cell death that can be prevented upon cathepsin inhibition.
Hence, to elucidate whether part of the cell death observed in
34-treated cells was due to a cathepsin-mediated process,
cells were incubated with 34, with or without a cathepsin in-
hibitor cocktail (cathepsin inhibitor III, EMD Millipore)
which primarily targets cathepsin B, and the extent of cell
death was then measured by an Annexin V-FITC/PI staining
assay. As shown in Fig. 4, the presence of the cathepsin in-
hibitor did not have any effect on the percentage of live cells
but on the contrary it did dramatically induce necrosis on
HGC-27 cells. Treatment of HGC-27 cells with cathepsin in-
hibitor III alone did not have remarkable apoptotic effects
(not shown). The obtained results discard the involvement of
LCD in the molecular mechanism responsible for 34 effects.
Necrosis. Initial cell death analysis by flow cytometry
studies revealed that 34 also causes a significant increase in
the number of necrotic cells (Fig. 4). Necrosis may be primary
or secondary. Secondary necrotic cells follow apoptosis,
whereas primary necrosis, also termed necroptosis, is a non-
apoptotic programmed cell death that is mediated by kinases
of the receptor interacting protein (RIP) family.33 Hence, we
then investigated if necroptosis could contribute to the
caspase-independent cell death. With this aim, HGC-27 cells
were pre-treated with Necrostatin-1 (Nec-1), an RIP1 inhibitor
that blocks this pathway. Interestingly, the necrosis induced
by 34 turned out to be not Nec-1 sensitive, thus discarding
the involvement of necroptosis as a cell death method, and
suggesting that the necrotic cells observed in the flow cytom-
etry analysis are probably post-apoptotic cells.
Autophagy. Apart from apoptosis or necrosis, another
mechanism of programmed cell death is associated with ex-
cessive levels of autophagy in a process known as autophagic
cell death (ACD).34 Considering that an autophagic pathway
could play a role in the 34-mediated effect, we determine
whether this compound induces autophagy in HGC-27 cells
and how this process may impact the cellular fate. Therefore,
we evaluated the effects of squaramide 34 on autophagy by
assessing a key marker of this process, LC3-II. During auto-
phagosome formation, microtubule-associated protein 1 light
chain 3 (LC3-I) gets lipidated at the C-terminus with a
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phosphatidylethanolamine unit (LC3-II) and subsequently as-
sociated with the autophagosome membrane. Since the
amount of LC3-II correlates well with the number of
autophagosomes, it has been widely employed to monitor
autophagy. Hence, HGC-27 cells were treated with 34 for 24
h, and the cell lysates were subjected to Western blotting to
determine the changes in expression of LC3-II. As shown in
Fig. 5, Western blot analysis revealed a minor increase in this
specific autophagic marker after squaramide 34 treatment.
Because autophagy is a dynamic process, LC3 accumulation
can occur as a result of autophagy induction or due to im-
pairment of the lysosomal function. Moreover, certain cells
present a high basal autophagic flux, and as a consequence,
autophagy induction is not always correlated with a clear
LC3-II accumulation.35 To discard these possibilities, LC3-II
levels were also measured upon inhibition of the lysosomal
function. Indeed, these studies revealed a pronounced accu-
mulation of LC3-II in 34-treated cells, indicating a correct
autophagic flux, an unmasked LC3-II accumulation probably
due to its rapid turnover and confirming an important
autophagy induction.
Although it has been proven that autophagy can contrib-
ute to cell death,36 there is still a controversy whether it is a
cell death caused by autophagy, or a cell death accompanied
by induction of autophagy that may exert a survival or
cytoprotective effect.37,38 To determine how this autophagy
induction impacts the cell fate, we aimed to test if autophagy
plays a causative role in preventing 34-induced cell death by
employing autophagy inhibitors. Herein, we used two auto-
phagy inhibitors, chloroquine (CQ), a lysosomotropic agent
that impairs the lysosomal function, and 3-methyladenine
(3-MA), a pan inhibitor of the lipid kinase phosphatidy-
linositol 3-kinase (PI3K), involved in the first steps of auto-
phagosome formation, and the percentage of apoptotic/
Fig. 5 HGC-27 cells were exposed to 34 for 24 h. A) Levels of LC3-II were assessed by Western blotting of cell lysates as described in the Experi-
mental procedures. XM462 (10 μM), a known autophagy inducer in HGC-27 cells, was used as a positive control.47 The images shown are repre-
sentative of three independent experiments with similar results. B) Quantified LC3-II levels with respect to β-actin. C) Effect of autophagy inhibition
on apoptosis/necrosis of treated HGC-27 cells. Cells were treated with DMSO (vehicle group), 34 alone, chloroquine (CQ, 50 μM in EtOH) or
3-methyladenine (3-MA, 2 mM in DMSO). The cells were pre-treated for 2 h with CQ or 3 h with 3-MA before adding 34. After 24 h of treatment,
the cells were double-stained with Annexin V and PI and analysed. The percentage of apoptotic and necrotic cells upon incubation with 34 were
quantified by flow cytometry as described in the Experimental section (live cells (bottom left quadrant), early apoptotic cells (bottom right quad-
rant), late apoptotic cells (upper right quadrant) and necrotic cells (upper left quadrant)). The graph shows the quantitative analysis of necrosis and
early and late apoptosis in cells treated with 34. The data were obtained from three independent experiments.
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necrotic and live cells upon autophagy inhibition was
analysed. As shown in Fig. 5, co-treatment of 34 with auto-
phagy inhibitors such as CQ or 3-MA did not increase the
number of live cells, but on the contrary significantly
increased the number of necrotic cells. Taken all together, all
data described above suggest that autophagy is triggered by
34 exposure to HGC-27 cells as a protective response to allevi-
ate its cytotoxicity. Moreover, the fact that cathepsin inhibi-
tion, which causes lysosomal dysfunction, results also in
increased cell death may underscore the pro-survival function
of autophagy, which requires a correct lysosomal function to
take place (Fig. 4).39
2.5. Mitochondria and ROS
MTT assays measure the activity of succinate dehydrogenase,
a mitochondrial enzyme, hence reflecting the activity status
of this organelle and suggesting that the differences observed
in both cell viability methods employed above (MTT vs. ATP-
based assay) may occur due to mitochondrial damage, which
would be in agreement with the increased viability upon
treatment with the caspase-9 inhibitor, a marker of the in-
trinsic mitochondrial pathway.
If the intrinsic mitochondrial pathway is activated, there
are alterations in the inner mitochondrial membrane,
resulting in changes in transmembrane potential, loss of
membrane permeability and activation of caspase. Therefore,
we next investigated the mitochondrial membrane potential
in HGC-27 cells treated with squaramide 34. JC-1 accumu-
lates as aggregates in the mitochondria (orange color) and
the color changes from orange to green fluorescence in apo-
ptotic cells with depolarization of mitochondrial membrane
potential, where JC-1 exists in the monomeric form.40 There-
fore, JC-1 has been widely used to detect mitochondrial depo-
larization during apoptosis. The results showed that 34
efficiently caused mitochondrial membrane depolarization.
When ΔΨm levels were assessed quantitatively by the ratio of
orange/green fluorescence intensity, there was a significant
reduction of ΔΨm in HGC-27 cells compared to control cells
after a 2 μM and 8 μM treatment for 24 h (Fig. 6), which indi-
cates that compound 34 induces ΔΨm changes in HGC-27
cells during apoptosis. These results confirmed the implica-
tion of the intrinsic pathway in the 34-mediated cell death.
Reactive oxygen species (ROS) are known triggers of the
intrinsic apoptotic cascade.41 Therefore, oxidative damage
caused by the generation of ROS may be one of the underly-
ing mechanisms of 34-mediated cell death. To elucidate
whether oxidative stress mediated by ROS generation plays a
critical role in the onset of cell death caused by 34, we deter-
mined the changes in the intracellular redox potential
upon treatment with 34 by employing the fluorescent probe
2′,7′-dichlorofluorescein diacetate (DCFH-DA), which is con-
verted to highly fluorescent dichlorofluorescein (DCF) in the
presence of intracellular ROS. However, although a remark-
able increase in ROS formation was detected when H2O2 was
employed as a positive control, no signs of ROS production
could be detected in HGC-27 treated cells, thus discarding
the implication of oxidative damage in the molecular mecha-
nism responsible for 34-mediated cell death (Fig. S2‡).
Summary and conclusions
In this study, it has been shown that substituted squaramide
34 effectively inhibited the proliferation of HGC-27 cells in a
concentration-dependent manner. These inhibitory effects
were associated with the cell cycle arrest and induction of ap-
optosis dependent of caspases that implicates the activation
of the intrinsic pathway and the subsequent mitochondrial
membrane depolarization. The implication of ROS as stimuli
for the activation of the intrinsic pathway has been
discarded, suggesting that other stimuli or pro-apoptotic pro-
teins may be involved in the activation of the intrinsic path-
way. Apart from the observed caspase-dependent apoptosis,
no signs of cathepsin-mediated cell death or necroptosis have
been detected. Moreover, the cell death caused by 34 is ac-
companied by autophagy induction having a protective effect.
These overall results indicate that the decrease in cell viabil-
ity caused by squaramide 34 is most likely mediated by G0/G1
cell cycle arrest and caspase-mediated apoptosis. Since the
identification of compounds inducing a specific cell death
subroutine is preferred to avoid side-effects and nonspecific
cytotoxic effects, squaramide 34 can be considered a promis-
ing agent for the treatment of gastric carcinoma. Moreover,
although 34 presents an specific effect on HGC-27 cells vs.
HeLa, U87 and T98 cells, similar anti-tumor effects on other
epithelial tumor types, particularly those of the GI tract, can-
not be discarded and will be characterized in future studies.
Experimental section
Materials
Minimum essential medium eagle, fetal bovine serum, non-
essential amino acids, 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT), BSA, NADH, Tween 20,
trypsin-EDTA, chloroquine diphosphate, 3-methyladenine,
necrostatin-1, pepstatin A, C8-ceramide, doxorubicin, 2′,7′-
Fig. 6 Mitochondrial membrane potential in 34-treated HGC-27 cells
evaluated by JC-1 staining and flow cytometry analysis. Quantification of
the orange/green ratio. Data are the average ± SD of three experiments.
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dichlorofluorescein diacetate and protease inhibitors were
obtained from Sigma. Laemmli buffer and acrylamide were
procured from BioRad, SDS from Fluka, and the microBCA
protein assay kit from Thermo Scientific. The protease inhibi-
tor cocktail contained 2 μg ml−1 aprotinin, 5 μg ml−1 leupeptin,
and 1 mM phenylmethylsulphonyl fluoride. Z-VAD-FMK and
E-64-D were acquired from Enzo Life Science. Z-IEDT-FMK
and Z-LEHD-FMK were purchased from Alfa Aesar and ca-
thepsin inhibitor III from CalBioChem. Annexin V-FITC early
apoptosis detection kit was obtained from Cell Signaling.
Antibodies: microtubule-associated protein 1-light chain 3
(LC3) II (rabbit) was obtained from Abcam, and β-actin
(mouse) was purchased from Sigma. HRP secondary anti-
bodies were acquired from GE Healthcare.
General experimental methods
Purification of reaction products was carried out either by
filtration or by flash chromatography using silica gel (0.063–
0.200 mm). Analytical thin layer chromatography was
performed on 0.25 mm silica gel 60-F plates. The ESI ioniza-
tion method and a mass analyzer type MicroTof-Q were used
for ESI measurements. 1H-NMR spectra were recorded at 300
and 400 MHz; 13C-NMR-APT spectra were recorded at 75 and
100 MHz; CDCl3 and DMSO-d6 were used as solvents. Chemi-
cal shifts were reported in the δ scale relative to residual
CHCl3 (7.26 ppm) and DMSO (2.50 ppm) for
1H-NMR and to
the central line of CDCl3 (77 ppm) and DMSO-d6 (39.43 ppm)
for 13C-NMR-APT. All commercially available solvents and re-
agents were used as received.
Representative procedure for the synthesis of squaramates
and squaramides
To a mixture of 3,4-dimethoxy-3-cyclobutene-1,2-dione
(0.2 mmol) in MeOH (0.75–1.5 ml), appropriate amine (0.2
mmol) was added at room temperature. After the appropriate
reaction time, the corresponding squaramate was purified ei-
ther by filtration, washing with MeOH at −25 °C, or column
chromatography (see the ESI‡). Squaramate 1 is commercially
available. The 1H and 13C-NMR spectral data for squaramates
2,42 3,10 4,42 9,42 and 10,42 are consistent with values previ-
ously reported in the literature. For spectral and analytical
data for all new squaramates (5–8 and 11–14), see the ESI.‡
Squaramides 15-39 were synthesized following our own
reported procedure.20,22 The 1H and 13C-NMR spectral data
for squaramides 15–18,43 19,44 20,1 21,20 22,20 23,20 24,20
25,20 26,1 27,45 28,20 29,46 30,43 31,20 32,20 33,20 34,20 35,20
36,20 37,45 38,20 and 39,20 are consistent with values previ-
ously reported in the literature.
Cell culture
The human gastric cancer cell line HGC-27 was cultured at
37 °C in 5% CO2 in minimum essential medium supple-
mented with 10% fetal bovine serum and 1% nonessential
amino acids. Cells were routinely grown at 80% maximum
confluence. Glioblastoma cells T98G and U87 as well as
HEK293 and HeLa cells were maintained at 37 °C in 5% CO2
in Dulbecco's modified Eagle's medium supplemented with
10% fetal bovine serum and 100 ng ml−1 each of penicillin
and streptomycin.
Cell viability assay
To determine cell viability, the colorimetric MTT metabolic
activity assay was employed. Cells were seeded at a density of
0.1 × 106 cells ml−1, 0.1 ml per well (96-well plates) and cul-
tured at 37 °C and 5% CO2. Twenty-four hours after seeding,
cells were exposed to varying concentrations of the investi-
gated compounds and viability was determined 24 h or 48 h
later. The control culture was prepared by addition of culture
medium (cell viability control) or DMSO (vehicle control) in
the absence of treatment. The stock solution of doxorubicin
was prepared in water. After 24 h or 48 h of treatment, MTT
solution (10 μl at 5 mg ml−1 in PBS) was added to each well
and the cells were incubated for another 3 h. The solution
was removed from the precipitate and the resulting formazan
crystals were dissolved in DMSO (100 μl) and the absorbance
intensity was measured using a microplate reader (Molecular
Devices, SpectramaxM5) at 570 nm. All experiments were
performed in triplicate, and the relative cell viability (%) is
expressed as the percentage of cell viability relative to the
cells treated with DMSO (0.1%, vehicle group).
SRB assay
Cells were seeded at a density of 0.1 × 106 cells per ml, 0.1 ml
per well (96-well plates) and cultured at 37 °C and 5% CO2.
Twenty-four hours after seeding, cells were exposed to varying
concentrations of 34 and viability was determined after 24 h.
The control culture was prepared by addition of DMSO
(vehicle control) in the absence of treatment. After 24 h, 50 μl
of TCA (50% w/v) and 200 μl of PBS were added to each well
and the cells were incubated for 1 h at 4 °C. The solution was
then removed and the plate was washed with Milli-Q water
four times. After that, 100 μl per well of SRB solution (0.4%
sulforhodamine B w/v in 0.1% acetic acid) was added and the
samples were incubated for another 30 min at room tempera-
ture. The plate was then washed with 1% acetic acid five
times and 200 μl of a 10 mM Tris solution (pH 10.5) were
added to each well. After 30 min of incubation at room tem-
perature, the absorbance intensity was measured using a
microplate reader (Molecular Devices, SpectramaxM5) at
564 nm. All experiments were performed in triplicate, and
the relative cell viability (%) is expressed as the percentage of
cell viability relative to the cells treated with DMSO (0.1%,
vehicle group).
Cell cycle analysis
Cells were seeded at 150 000 cells per ml in 6-well plates
(1 ml per well). Cells were allowed to adhere for 24 h, and
then they were treated with the vehicle (0.1% ethanol) or 34.
After exposure for 24 h, cell media were discarded and cells
were washed with 400 μl of PBS–EDTA (1% BSA) and
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harvested with 400 μl of trypsin–EDTA (1% BSA) (37 °C per
2 min). Cells were pulled down by centrifugation at 1300 rpm
per 3 min; the cell pellet was washed once with 400 μl of
PBS–EDTA (1% BSA) and again centrifuged at the same
speed/time. Cells were fixed by −20 °C overnight incubation
with 70% ethanol (9.5 ml) in 1 × PBS solution (0.5 ml). Fixed
cells were pulled down, washed once with PBS–EDTA
(1% BSA) and stained at 37 °C for 2 h with propidium iodide
solution (0.1 mg ml−1 in PBS) and RNase, DNase-free (10 μg
ml−1). Stained cells were analyzed by using a Guava
EasyCyte™ flow cytometer (Merck Millipore, Billerica, MA).
Data analysis was performed using the program Multicycle
AV (Phoenix Flow Systems, San Diego, CA).
Apoptosis assay
HGC-27 cells were plated in 6-well plates (100 000 cells per
ml per well) and were treated with compound 34; 0.1%
DMSO was used as a vehicle control. After induction for 24 h,
both treated and untreated cells were collected (trypsin and
PBS with 5% BSA) and the cells were washed with PBS
containing 5% BSA. The percentages of apoptotic cells were
estimated by staining with Annexin-V-FITC and PI (Annexin-V-
FITC apoptosis detection kit, Cell Signaling). Almost 10 000
events were collected for each sample and analyzed by flow
cytometry. In brief, cells were incubated with 96 μl of binding
buffer, 1 μl of Annexin V-FITC and 12.5 μl of PI solution at
room temperature for 10 min in the dark. After a final addi-
tion of 150 μl of PBS, HGC-27 cells were immediately ana-
lyzed on a Guava EasyCyte™ single sample flow cytometer.
Samples were excited by a light wavelength of 488 nm with
barrier filters of 525 nm and 575 nm for FITC fluorescence
and PI detection, respectively. Data were analyzed by InCyte
Software and plotted for Annexin V-FITC and PI in a two-way
dot plot. Live, early apoptotic, late apoptotic and necrotic
cells are designed as Annexin−/PI−, Annexin+/PI−, and
Annexin+/PI+, respectively. Results are shown as the percent-
age of cells.
Western blotting
For protein analysis, 1 × 105 cells were plated in 6-well plates
and were allowed to adhere for 24 h. In the samples
containing protease inhibitors, cells were treated with prote-
ase inhibitors, 1 μl of pepstatin A at a concentration of 1 mg
ml−1 in 9 : 1 of methanol and acetic acid (1%), and 1 μl of
E-64-D at a concentration of 10 mg ml−1 in ethanol. After 2 h
of incubation, HGC-27 cells were treated with 34 (2 μM) or
DMSO (0.1%) for 24 h, collected with trypsin, and then the
pellets were washed twice with cold PBS. Cell lysis was
performed with 30 μl of lysis buffer (50 mM Tris-Cl (pH 7.5),
150 mM NaCl, 0.5% Triton X-100, 2 μg ml−1 aprotinin, 5 μg
ml−1 leupeptin and 1 mM PMSF) by five cycles of bath sonica-
tion (20 s)/rest on ice (20 s). Then samples were kept on ice
for 30 min and centrifuged for 3 min at 10 000 rpm. Super-
natants were collected and protein determination was
performed using the Micro BCA™ protein assay kit. Superna-
tants were combined with Laemmli sample buffer and boiled
for 5 min. Equal amounts of proteins (20 μg) were loaded
onto a 15% polyacrylamide gel, separated by electrophoresis
at 140 V per 60 min, and transferred onto a polyvinylidene
fluoride (PVDF) membrane (100 V/1 h). PVDF membranes
were then cut to separate LC3B and β-actin bands. Unspecific
binding sites were then blocked with 5% milk in TBS with
0.1% Tween 20 (TBST) in the case of the LC3B membrane
and with 3% BSA in TBST in the case of the anti-β-actin anti-
body. The anti-LC3B antibody was diluted 1 : 1000 in 5% milk
in TBST, and the anti-β-actin antibody was diluted 1 : 2000 in
3% BSA in TBST. Membranes were incubated overnight at
4 °C under gentle agitation. After washing with TBST, mem-
branes were probed with the corresponding secondary anti-
body for 1 h at 25 °C (LC3B: 1 : 1000 dilution in 3% BSA in
TBST; actin: 1 : 10 000 dilution in 5% milk in TBST). Antibody
excess was eliminated by washing with TBST and protein de-
tection was carried out using ECL and membrane scanning
with a LI-COR C-DiGit® blot scanner. Band intensities were
quantified by LI-COR Image Studio Lite Software. All experi-
ments were performed in triplicate and band intensities were
expressed as the relation of the samples with the control.
Mitochondrial membrane potential
HGC-27 cells were seeded at a density of 100 000 cells per ml
(1 ml per well) in 6-well plates, cultured at 37 °C and 5%
CO2, and allowed to adhere for 24 h. Cells were treated with
34 at various concentrations (1 μM, 2 μM, 8 μM in DMSO) or
DMSO (0.2%) as negative control (vehicle group). After 24 h
of incubation, cells were collected (trypsin with 5% BSA) and
washed with PBS containing 5% BSA. The cell pellet was then
resuspended in 200 μl of medium and seeded in a 96-well
plate (1 sample per well). 4 μl of a previously prepared 50×
solution of JC-1 and 7-AAD were added to each well and cells
were incubated for 30 min at 37 °C and 5% CO2. Finally, cells
were collected in Eppendorf flasks and analysed on a Guava
EasyCyte™ Single Sample Flow Cytometer. Data were ana-
lyzed by InCyte Software and plotted for orange (JC-1 aggre-
gates) and green fluorescence (JC-1 monomers).
ROS detection
The oxidative metabolism was examined in triplicate samples
by using 2′,7′-dichlorofluorescein diacetate, a non-fluorescent
membrane-permeable compound which can be oxidised to
2′,7′-dichlorofluorescein in case the cell has high levels of re-
active oxygen species.
HGC-27 cells were seeded at a density of 0.1 × 106 cells
per ml, 0.1 ml per well (96-well plates), cultured at 37 °C and
5% and allowed to adhere for 24 h. 2′,7′-Dichlorofluorescein
diacetate (25 μM) in DMSO was then added and incubated
for 1 h. Compound 34 was then added at various concentra-
tions (24 to 1.40 μM). DMSO and H2O2 were added too as a
negative and positive control, respectively. After 5 h of incu-
bation, fluorescence was measured by a microplate reader
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(Spectramax) at an excitation wavelength of 485 nm and an
emission wavelength of 538 nm.
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